BPC-157 vs TB-500

BPC-157 vs TB-500 as molecules

The fastest way to see how different BPC-157 vs TB-500 really are is to put their specifications side by side. One is more than twice the length of the other and over half again its mass, and they have no residues in common beyond what any two peptides would share by chance.

Both are supplied here as white lyophilised material in 10mg vials, both dissolve readily in bacteriostatic water, and both carry an independently assayed certificate against the lot number on the vial. That is the extent of what they have in common.

One shared absence is worth flagging at the start, because it comes back three times further down. Neither sequence contains cysteine, methionine, tryptophan, tyrosine or phenylalanine. That single fact rules out two whole classes of degradation, rules out one class of protease, and decides the wavelength at which each is detected on a chromatogram.

BPC-157 vs TB-500: two different origins

On origin, BPC-157 vs TB-500 divides cleanly. BPC-157 is a laboratory construct. Its sequence corresponds to a fifteen-amino-acid stretch of a larger protein identified in gastric juice and designated Body Protection Compound, from which the abbreviation comes. The fragment itself does not occur as a free peptide in nature: it was synthesised because that region was the part of interest.

TB-500's origin is different in kind. Thymosin beta-4 is a real, 43-residue protein found widely in cells, where it is the principal actin-sequestering molecule. TB-500 is a seven-residue acetylated fragment corresponding to a short region of it.

That distinction is worth making precisely because the two names are so often used interchangeably. TB-500 is not thymosin beta-4. It is roughly a sixth of its mass and does not carry the rest of the protein's structure, and preclinical work on one does not automatically describe the other.

The seven residues are not an arbitrary slice of the parent. LKKTETQ corresponds to residues 17 to 23 of thymosin beta-4, the stretch associated with the protein's actin-binding behaviour, which is why that region and not another was worth making on its own. The parent protein was first isolated from thymus tissue and sequenced in 1981; Sanders, Goldstein and Wang established it in PNAS in 1992 as a principal regulator of the cell's unpolymerised actin pool, pairing with actin at roughly one to one.

BPC-157 carries a second name from the same period. In the patent and development literature the identical fifteen-residue sequence appears as PL 14736, a company code rather than a different molecule. A fuller profile of the BPC-157 peptide sets the designations out against each other.

BPC-157 vs TB-500: same vial weight, different molecule count

Both compounds ship in a 10mg vial, which makes BPC-157 vs TB-500 look like matched quantities. They are not, and the reason is the mass difference in the table above.

Ten milligrams divided by the molecular weight gives the amount of substance in the vial. For BPC-157, 10 mg is 7.04 micromoles. For TB-500, the same 10 mg is 11.25 micromoles. The TB-500 vial holds about 60% more molecules than the BPC-157 vial for an identical printed weight, because each of its molecules weighs 37% less.

This is arithmetic, not chemistry, and it is why a labelled weight is a poor basis for comparing two different peptides. Molar concentration is the unit that counts molecules; milligrams count grams. Nobody ranking for this comparison states either mass, so nobody states this either. It is the single clearest way to see that the two are not interchangeable quantities of a similar thing.

Reconstitution: what 10 mg of each becomes

Reconstitution is arithmetic and it stops at concentration. The mass in the vial and the volume of diluent are the only two inputs, so the milligram-per-millilitre figure is the same for both compounds: 10 mg in 1 mL is 10 mg/mL, in 2 mL is 5 mg/mL, in 3 mL is 3.33 mg/mL, in 5 mL is 2 mg/mL. The peptide calculator runs the same division for any vial strength and volume, and takes the net peptide content from the certificate rather than the label mass as its starting figure.

The molar concentration is not the same, for the reason set out above. Five milligrams per millilitre is 3.52 mM of BPC-157 and 5.62 mM of TB-500. Two solutions that read identically on a label are 60% apart in the unit that matters to a binding experiment.

The diluent is the same for both. Bacteriostatic water is sterile water carrying 0.9% benzyl alcohol as a bacteriostatic preservative, which is what allows a reconstituted vial to be drawn from more than once; the 28-day in-use period that applies once the closure has been entered comes from USP General Chapter <797>'s default beyond-use date for a multiple-dose container and from CDC injection-safety guidance rather than from the FDA label, which does not carry the number at all, and it governs the water rather than the peptide dissolved in it. Plain sterile water carries no preservative and has no in-use period of that kind. Choosing bacteriostatic water for peptides turns on that difference and on nothing else.

Once either peptide is in solution it stops being the stable form. Sealed cake sits at −20°C; solution sits at 2 to 8°C and has a working life. The section on degradation below explains what water is actually doing to each sequence in the meantime.

Salt form, counterion and net peptide content

A peptide with basic residues is almost never isolated as the free base. It comes off reverse-phase purification as a salt, most often the trifluoroacetate, because reverse-phase purification is normally run with trifluoroacetic acid in the mobile phase and that is the counterion the chain leaves the column paired with. Other counterions appear: acetate where the material has been through a deliberate ion-exchange step afterwards, arginate and hydrochloride in some preparations. Each of them has a different mass.

That mass is part of what the vial weighs. Ten milligrams of BPC-157 trifluoroacetate is not ten milligrams of the fifteen-residue chain; some fraction is counterion and some is residual water, and the fraction depends on how many basic sites the sequence carries. BPC-157 has one lysine and a free N-terminal amine. TB-500 has two lysines and an acetylated N-terminus, the acetyl group having removed the alpha-amino group that would otherwise be the third. Both therefore present two basic sites, which is why BPC-157 vs TB-500 behave more similarly here than their sizes suggest.

This is the reason a certificate reports a measured content figure and not only a purity percentage. Peptide purity is the proportion of the chromatogram that is the right molecule. Content is how much peptide the vial actually holds. On the lots currently released those figures are 10.68 mg for BPC-157 lot 2FRBRG and 12.16 mg for TB-500 lot PQ7MWD, both against a nominal 10mg fill. A purity percentage on its own tells you nothing about either number.

When a supplier quotes a purity figure and no content figure, the salt form is where the missing weight goes. It is one of the few places in this subject where two vials with identical labels can genuinely differ.

What can actually degrade in each sequence

In BPC-157 vs TB-500 one absence is shared. Neither sequence contains cysteine or methionine. That removes the two commonest chemical failure modes for peptides in solution at a stroke: there are no thiols to oxidise and no disulfide bonds to scramble or mispair. Whatever else is true of these two compounds, those particular problems are not available to them.

What each does carry is different, and specific. TB-500 ends in glutamine. A C-terminal glutamine is a deamidation site: the side-chain amide hydrolyses to a carboxylic acid, the residue becomes glutamate, and the molecule becomes roughly 0.98 daltons heavier. That is a small shift and a real one, and mass spectrometry is precisely where it would show against a theoretical 889.0.

BPC-157 carries two adjacent aspartates, at positions 10 and 11. Aspartate can cyclise through a succinimide intermediate and reopen as isoaspartate. That is an isomerisation, not a change of composition, so the mass does not move at all: it appears as a retention-time shift and a shoulder beside the main peak on the chromatogram. It is a useful illustration of why a purity figure is read off a chromatogram rather than inferred from a mass.

BPC-157 is also unusually proline-rich: four of its fifteen residues are proline, the PPP run at positions 3 to 5 and a fourth at position 8. Proline has no amide hydrogen on its backbone nitrogen, which constrains the chain's conformation and makes those particular bonds poor substrates for a good many endopeptidases.

All of this is why both are supplied as lyophilized powder rather than as a liquid. Water is a reagent in deamidation and in succinimide hydrolysis; take it out and both processes slow to the point that a sealed vial at −20°C is stable over years while the same material in solution is not. How to store peptides follows from the chemistry rather than from convention.

Peptide bonds and protease chemistry

A peptide bond is a substrate. Proteases recognise particular residues on either side of it and hydrolyse it, and which residues a sequence contains determines which enzymes can act on it at all. This matters to anyone incubating either compound in a biological matrix, whether serum, a cell lysate or simulated gastric or intestinal fluid, where recovering the intact peptide is what the measurement depends on.

Trypsin cleaves on the C-terminal side of lysine and arginine, and does not cleave when the following residue is proline. BPC-157 has one lysine, at position 7, and the residue after it is proline. Its single tryptic site is blocked. TB-500 has two lysines, at positions 2 and 3, and neither is followed by proline, so a seven-residue chain carries two open tryptic sites.

Chymotrypsin cleaves after aromatic residues. Neither sequence contains tryptophan, tyrosine or phenylalanine, so chymotrypsin is not a route for either one, and pepsin, which also favours hydrophobic and aromatic positions, has little to work with. The exposure of BPC-157 vs TB-500 to the standard proteolytic enzymes is therefore quite different, and it is readable straight off the sequences.

None of that is a statement about what happens to either compound anywhere other than in an assay vessel. It is the same class of fact as a melting point: it says what the molecule is made of, and what that composition implies for a molecule sitting in a particular solution.

What each is studied for

BPC-157 vs TB-500 occupy different preclinical literatures, which is a more useful way to distinguish them than any comparison of potency.

BPC-157 appears in tissue-repair and cytoprotection models: angiogenesis markers in wound-healing systems, vascular endothelial growth factor receptor expression in endothelial-migration assays, gastrointestinal cytoprotective signalling in rodent mucosal models, connective-tissue endpoints in tendon-fibroblast cultures, and peripheral nerve preparations. TB-500 appears in work on actin regulation: actin sequestration, cell-migration rate in scratch-assay systems, and vascular-repair endpoints.

One scope limit is worth stating plainly, because the literature is routinely quoted across it. The binding figures published for thymosin beta-4, the roughly one-to-one pairing with actin and the micromolar affinities reported in the beta-thymosin literature, describe the 43-residue parent protein. They do not describe the seven-residue fragment, and a page that cites them beside a TB-500 vial has crossed from one molecule to another.

Both literatures are preclinical. Neither is a statement about effect in humans, and nothing here is one: these compounds are supplied for in-vitro research use only, and the models above are described as models.

Names you will see for the same material

Almost every page written on BPC-157 vs TB-500 uses at least two names for one of the two compounds without saying they are the same thing, and at least one name for a molecule that is not the one in the vial. The table sorts them out.

Two entries deserve a sentence of their own. Thymosin beta-4 is not a synonym for TB-500: it is the 43-residue parent, about 5.6 times the mass, and using the two names interchangeably is how binding figures from the parent end up quoted for the fragment. And a trade nickname for the two together is not a formulation: it has no defined ratio, no defined component list and no standard behind it, so what it covers varies from one supplier to the next. GLOW vs KLOW is the opposite case: named components at stated weights, each assayed separately.

BPC-157 vs TB-500: telling the two vials apart by certificate

Both cakes are white and both vials are 10mg. By eye there is nothing to tell them apart, and no amount of looking at a vial will settle which molecule is in it. The certificate will.

The identity line on a certificate reports an observed mass from LC-MS against a theoretical mass. For BPC-157 that theoretical figure is 1419.53; for TB-500 it is 889.0. The gap between them is 530.53 daltons, which is not a fine discrimination: any instrument capable of the measurement at all separates the two without difficulty. If the observed mass sits near one figure, that is what is in the vial, whatever the label says.

Purity is a separate measurement, by reverse-phase HPLC. Because neither peptide contains tryptophan or tyrosine, neither has useful absorbance at 280 nm, so detection is at the peptide-bond absorbance near 214 nm. That is standard for sequences of this composition and it is worth knowing when reading a chromatogram whose axis you did not choose.

Our BPC-157 lot 2FRBRG and TB-500 lot PQ7MWD were both assayed by Freedom Diagnostics, an independent laboratory named on the certificate, reported on 29 May 2026. Each certificate carries an accession number, 2605270306 and 2605270305, and a search code, so the document can be checked at the laboratory rather than taken on our word. The TB-500 certificate for that lot also reports an endotoxin result, pass on both replicates by LAL at ≤0.05 EU/mL. Reading a peptide certificate of analysis line by line explains the remaining fields, and peptide purity testing explains who is measuring what.

What a single blended purity figure hides

GLOW holds GHK-Cu 50mg, BPC-157 10mg and TB-500 10mg in one vial. KLOW adds KPV 10mg to the same three. A blend can be documented two ways, and the difference is not cosmetic.

Reported as one number, the figure is a weight-weighted average dominated by whichever component is largest. Take an illustrative 70mg blend in which the 50mg component assays at 99.9% and the two 10mg components at 97%: the blended average is 99.1%, which reads as an excellent figure while saying nothing at all about the two components a reader came for. The arithmetic is not a trick; it is simply what an average of unequal weights does.

Reported per component, each assay stands on its own and the reader can see all three or all four. That is how GLOW and KLOW are documented here: the headline figures are 99.68% and 99.76%, and the certificate behind each breaks the blend out component by component rather than resolving it to one line.

The same logic is the argument for two separate vials where a model system does not require a fixed ratio. For BPC-157 vs TB-500, two vials means two certificates, two content figures and two independent reconstitutions at known concentrations, which is what the Repair Reference Panel is.

Regulatory status, stated as fact

Neither compound is an approved drug product. There is no approved medicine containing BPC-157 or TB-500, for any indication, anywhere, and nothing here is offered as one. Both are supplied for in-vitro laboratory research only.

BPC-157 sits in Category 2 of the FDA's interim 503A bulk drug substances list, the category for substances the agency has identified as raising significant safety questions while nominations are under review, which means a 503A compounding pharmacy may not compound it. The Pharmacy Compounding Advisory Committee met on 23 and 24 July 2026 and voted to recommend inclusion of specified free-base and acetate forms related to BPC-157; those votes are advisory and final agency action was still pending when this was written.

Both compounds appear on the WADA Prohibited List, and both are prohibited at all times rather than in competition only. The US Anti-Doping Agency states that BPC-157 was added to the 2022 list under S0, non-approved substances. Thymosin beta-4 and its derivatives, TB-500 among them, fall under S2, peptide hormones and growth factors. That is a statement about eligibility in sport and it is recorded here because it is a fact about the compounds' status, not because a research catalogue has any bearing on it.

TB-500's position on the 503A list has not been checked against the current published version for this article, and the row below says so rather than guessing.

Buying either one

In BPC-157 vs TB-500 the practical difference between two vials of research material is rarely the molecule and almost always the documentation. Both of these are simple, well-characterised peptides that any competent synthesis house can make; what varies between research peptide suppliers is whether the specific lot in front of you was measured.

Ours are. BPC-157 released at 99.51% and TB-500 at 99.58% by HPLC, each with a mass-spectrometry identity confirmation, each assayed by an independent laboratory, and each certificate published against the lot number printed on its vial before it ships.

They are also supplied together in the Repair Reference Panel and, with GHK-Cu, inside the GLOW and KLOW blends, where each component is assayed and reported separately rather than as a single blended figure. The table sets out what actually ships, and how parcels are packed and sent covers the rest.